Conference Coverage (ASCO)

Active Specific Immunotherapy Mediates Tumor Regression

Published in Cancer Weekly, July 12th, 1999

Active specific immunotherapy with an autologous tumor vaccine, combined with recombinant granulocyte macrophage-colony stimulating factor (GM-CSF), either with or without interferon alfa-2B (IFN alfa-2b), mediated tumor regression in stage IV melanoma patients.

In a previous study, researchers from the University of California/Mount Zion Cancer Center, California, demonstrated tumor regression in stage IV melanoma patients following vaccination with autologous tumor cells (ATCs) and recombinant human GM-CSF (rhGM-CSF) (SPL Leong et al., J of Immunotherapy, in press).

At the 35th Annual Meeting of the American Society of Clinical Oncology, held May...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1999-07-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry